Analysis: St. Jude Medical Inc (NYSE:STJ) Price Target Upgraded Today
In an analyst note sent to clients and investors by Leerink Swann on Monday morning, the firm, St. Jude Medical Inc (NYSE:STJ), had their target price per share cut to $80.00. Analusts presently have a solid Outperform rating on the stock.
From a total of 22 analysts covering St. Jude Medical Inc. (NYSE:STJ) stock, 14 rate it a ”Buy”, 1 a “Sell”, and 9 a ”Hold”. This means that 58% of the ratings are positive. The highest target price is $89 while the lowest target price is $59. The mean of all analyst targets is $74.45 with a 29.32% above today’s ($61.57) stock price. St. Jude Medical Inc. was the topic of 22 analyst reports since July 21, 2015 according to the firm StockzIntelligence Inc. Credit Suisse maintained shares on October 22 with “Outperform” rating. Oppenheimer maintained shares with “Market Perform” rating and $79 target share price in a report from a September 2. RBC Capital Markets maintained STJ stock in a recent report from October 22 with “Sector Perform” rating. Evercore maintained the rating on September 1. Evercore has a “Hold” rating and a $80 price target on shares. Finally, BTIG Research maintained the stock with “Buy” rating in a report issued on a September 6.
Approximately 226,498 shares of stock traded hands. St. Jude Medical, Inc. (NYSE:STJ) has declined 14.16% since May 4, 2015 and is downtrending. It has underperformed by 13.08% the S&P500.
The overall sentiment of institutions has increased to 1.36 in Q2 2015. Its up 0.53, from 0.83 in 2015Q2. The ratio increased, as 53 institutions have sold all the shares of St. Jude Medical, Inc. that they owned while 170 funds have taken shares off the table. 68 funds have purchased shares for the first time while 235 added to their positions. These institutions now hold 225.36 million shares or 4.37% less than the 235.67 million shares they owned in 2015Q2.
The Fund Perkins Capital Management Inc currently is holding shares equating to 6.69% of its total portfolio in St. Jude Medical, Inc. representing a total of 95,338 shares. Another fund,Conatus Capital Management Lp, is holding a total of 1.45 million shares equating to 5.79% of their holdings. Additionally, Endurant Capital Management Lp has a 245,526 share stake in St. Jude Medical, Inc. which represents 5.17% of their total portfolio. The Fund, Garland Capital Management Inc, based out of Washington, has also built up a stake in the stock, which represents a total of 4.21% of their total portfolio. Finally Sanders Capital Llc, a fund which is based in the state of New York reported a total holdings of 4.88 million shares.
Insider activity is a very important aspect to track on any stock. Going back to April 24, 2015, shareholders of St. Jude Medical, Inc. have witnessed 0 insider purchases, and a total of 2 selling transactions equating to a net activity of approximately $7.46 million . Murphy Mark W. sold 859 shares worth approximately $62,698. Starks Daniel J sold 100,000 shares worth approximately $7.39M. Zellers Jason sold 396 shares worth approximately $28,924. Hill Barbara B sold 3,229 shares worth approximately $229,711. The company insider Fecho Jeff sold 5,174 shares worth $369,786.
St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The company has a market cap of $17.55 billion.
According to Zacks Investment Research, “St. Jude Medical, Inc. is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation.” Get a free copy of the Zacks research report on St. Jude Medical, Inc. (STJ).